Poland· PL-100230978
Epirubicin Accord
A epirubicin product containing epirubicini hydrochloridum, registered in Poland by Accord Healthcare Polska Sp. z o.o.. The same ATC class is registered in 17 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Epirubicin is registered in 17 of 19 countries.
Countries holding a registration under ATC L01DB03 (epirubicin), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 10 of them publish a price we can compare per daily dose
Epirubicin · ATC L01DB03
17 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of epirubicin costs, country by country.
Normalised to the WHO defined daily dose (7 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Epirubicin · price per daily dose (7 mg)
USD · FX 28 Sept 2026
- CH Switzerland$15.02
The record
At a glance
URPL (Poland)- Active substance
- Epirubicini hydrochloridum
- Manufacturer
- Accord Healthcare Polska Sp. z o.o.
- Country
- Poland (PL)
- ATC code
- L01DB03
- ATC class
- Epirubicin
- Defined daily dose
- 7 mg, P
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 5
- gtin05909991029869
- gtin05909990796373
- gtin05909990796380
- gtin05909990796397
- gtin05909990796403
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
560 interactions on record for epirubicin.
Graded by severity as the source publishes them — 100 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Epirubicin · interactions on record
560 records
- 100 severe
- 450 moderate
- 10 minor
Most severe, free to view
- CimetidineA02BA01severe
- PapaverineA03AD01severe
- CisaprideA03FA02severe
- DolasetronA04AA04severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Epirubicin in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumEpirubicine Sandoz 2 mg/mlSandoz
- CzechiaEPIRUBICIN ACCORDACCORD HEALTHCARE POLSKA Sp. z o.o., Varšava
- United StatesEllencePharmacia & Upjohn Company LLC
- FinlandEpirubicin Fresenius KabiFresenius Kabi Oncology Plc.
- SpainEPIRUBICINA ACCORD 2 mg/ml SOLUCION INYECTABLE O PARA PERFUSION EFGAccord Healthcare S.L.U.
- IrelandEpirubicin 2 mg/ml Solution for InjectionSeacross Pharma (Europe) Limited
- SwedenEpirubicin Accord 2 mg/ml Injektions-/infusionsvätska, lösningAccord Healthcare B.V.
- NorwayEpirubicin AccordAccord Healthcare B.V.
Authorised across Europe · EMA
The same active substance is authorised in 28 EEA countries. Names it is sold under:
- Austria · Epirubicin Accord, Epirubicin Ebewe
- Belgium · Epirubicin Ab, Epirubicin Eugia
- Bulgaria · Епирубицин Ебеве, Еписиндан
- Cyprus · Epirubicin Aqvida, Farmorubicin
- Czechia · Epirubicin Accord, Epirubicin Teva
- Germany · Bendaepi, Epi
- Denmark · Epirubicin "medac", Epirubicin Accord
- Estonia · Epirubicin Accord
- Spain · Epirubicina Accord, Epirubicina Aurovitas
- Finland · Epirubicin Accord, Epirubicin Ebewe
- France · Epirubicine Accord, Epirubicine Hikma
- United Kingdom (Northern Ireland) · Epirubicin, Epirubicin Hydrochloride Accord Healthcare
- Greece · Epirubicin Hydrochloride Pharmachemie, Epirubicin Viatris
- Hungary · Epirubicin Accord, Epirubicin Sandoz
- Ireland · Epirubicin Hydrochloride Accord Healthcare Ireland, Epirubicin Seasec Pharmaceutical
- Iceland · Epirubicin Actavis
- Italy · Epirubicina Ahcl, Epirubicina Hikma
- Lithuania · Epirubicin Accord
- Luxembourg · Epirubicin Eugia, Epirubicine Teva
- Latvia · Epirubicin Accord
- Malta · Epirubicin Hydrochloride Accord Healthcare
- Netherlands · Epirubicine Hcl Pharmachemie, Epirubicine Hikma
- Norway · Epirubicin Accord, Epirubicin Ebewe
- Portugal · Epirrubicina Accord, Epirrubicina Adoh
- Romania · Epirubicină Teva
- Sweden · Epirubicin Accord, Epirubicin Ebewe
- Slovenia · Epirubicin Ebewe, Epirubicin Teva
- Slovakia · Epimedac, Epirubicín Accord
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/43c32981-76f6-4e3d-829d-c13d03ced18e GET /v1/drugs/43c32981-76f6-4e3d-829d-c13d03ced18e?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Roztwór do wstrzykiwań / do infuzji",
"source": "urpl",
"strength": "2 mg/ml",
"packaging": "05909991029869 ¦ Lz ¦ 36547\n1 fiol. 50 ml\n05909990796373 ¦ Lz ¦ 59726\n1 fiol. 5 ml\n05909990796380 ¦ Lz ¦ 59728\n1 fiol. 10 ml\n05909990796397 ¦ Lz ¦ 59729\n1 fiol. 25 ml\n05909990796403 ¦ Lz ¦ 59731\n1 fiol. 100 ml",
"substance": "Epirubicini hydrochloridum 2 mg/ml",
"common_name": "Epirubicini hydrochloridum",
"pl_product_id": "100230978",
"pozwolenie_nr": "17072",
"auth_procedure": "DCP",
"authorisation_validity": "Bezterminowe"
}See everything about epirubicin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.